Advances in metabolic engineering of macrolide antibiotics.
- Author:
Tianyi HAO
1
;
Weiqing HE
1
Author Information
- Publication Type:Review
- Keywords: carrimycin; macrolide antibiotics; metabolic engineering; polyketide synthase; synthetic biology
- MeSH: Anti-Bacterial Agents; Bacteria/genetics*; Macrolides; Metabolic Engineering; Polyketide Synthases
- From: Chinese Journal of Biotechnology 2021;37(5):1737-1747
- CountryChina
- Language:Chinese
- Abstract: 14- to 16-membered macrolide antibiotics (MA) are clinically important anti-infective drugs. With the rapid emergence of bacterial resistance, there is an urgent need to develop novel MA to counter drug-resistant bacteria. The targeted optimization of MA can be guided by analyzing the interaction between the MA and its ribosomal targets, and the desired MA derivatives can be obtained efficiently when combining with the rapidly developed metabolic engineering approaches. In the past 30 years, metabolic engineering approaches have shown great advantages in engineering the biosynthesis of MA to create new derivatives and to improve their production. These metabolic engineering approaches include modification of the structural domains of the polyketide synthase (PKS) and post-PKS modification enzymes as well as combinatorial biosynthesis. In addition, the R&D (including the evaluation of its antimicrobial activities and the optimization through metabolic engineering) of carrimycin, a new 16-membered macrolide drug, are described in details in this review.
